secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001999371-25-014776
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Pharmaceuticals plans Phase 2 trial of TNX-102 SL for MDD in 2026, Phase 2/3 of TNX-4800 for Lyme in 2027
--------------------------------------------------------------------------------

- Phase 2 trial of TNX-102 SL for major depressive disorder expected to start in 2026.
- Phase 2/3 study of TNX-4800 for seasonal Lyme disease prevention expected to start in 2027.
- TNX-102 SL is currently FDA-approved for fibromyalgia; this expands its potential indication.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125014776/0001999371-25-014776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125014776/tnxp-8k_100725.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-014776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer